1
|
Liao C, Huang W, Lin M, Li H, Zhang Z, Zhang X, Chen R, Huang M, Yu P, Zhang S. Correlation of KMT2 family mutations with molecular characteristics and prognosis in colorectal cancer. Int J Biol Markers 2022; 37:149-157. [PMID: 35505597 DOI: 10.1177/03936155221095574] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND Lysine methyltransferase 2 (KMT2) family proteins methylate lysine 4 on histone H3 (H3K4) to promote genome accessibility and transcription. Dysregulation or mutation of KMT2 family have been observed frequently in various types of human cancers. Colorectal cancer is the third most common cancer worldwide. However, few studies have evaluated the role of KMT2 family mutations in colorectal cancer. The present study aimed to explore the impact of KMT2 family mutations on clinicopathological, molecular characteristics and prognosis in colorectal cancer. METHODS A total of 316 colorectal cancer patients were enrolled; tumor tissue and matched peripheral blood samples were collected and subjected to targeted sequencing with a panel of 1021 cancer-related genes. The association of clinical pathological features and molecular characteristics in patients were then analyzed. The cBioPortal dataset was used for investigating the KMT2 family mutations data and their correlation with clinical outcomes. RESULTS The overall mutation frequencies of KMT2A-D were 9.5%, 0.5%, 13%, and 13%, respectively, which were more often present at right-sided primary and earlier stage tumors. KMT2A-D mutations are associated with enhanced genomic instability, including a higher level of microsatellite instability (MSI-H) and tumor mutational burden (TMB-H). In addition, our results highlight the co-occurring gene mutations within the Wnt signaling, ERBB2/4, TGF-β superfamily pathway, and PI-3-kinase pathway in KMT2-mutant colorectal cancer. KMT2 family mutations were predictive biomarker for better overall survival in metastatic colorectal cancer. CONCLUSIONS Collectively, we identified that KMT2 family mutations were correlated with higher-TMB and higher-MSI, thus resulting in a better outcome for colorectal cancer patients.
Collapse
Affiliation(s)
- Cun Liao
- Department of Colorectal & Anal Surgery, 117742The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - Wei Huang
- Department of Colorectal & Anal Surgery, 117742The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - Minglin Lin
- Department of Colorectal & Anal Surgery, 117742The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - Hui Li
- Department of Colorectal & Anal Surgery, 117742The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - Zihan Zhang
- Department of Colorectal & Anal Surgery, 117742The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - Xiaolong Zhang
- Department of Colorectal & Anal Surgery, 117742The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | | | | | | | - Sen Zhang
- Department of Colorectal & Anal Surgery, 117742The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| |
Collapse
|
2
|
Laukhtina E, Lemberger U, Bruchbacher A, Ilijazi D, Korn S, Berndl F, D’Andrea D, Susani M, Enikeev D, Compérat E, Shariat SF, Hassler MR. Expression Analysis and Mutational Status of Histone Methyltransferase KMT2D at Different Upper Tract Urothelial Carcinoma Locations. J Pers Med 2021; 11:jpm11111147. [PMID: 34834500 PMCID: PMC8625702 DOI: 10.3390/jpm11111147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Revised: 10/30/2021] [Accepted: 11/02/2021] [Indexed: 11/16/2022] Open
Abstract
The gene coding for histone methyltransferase KMT2D is found among the top mutated genes in upper tract urothelial carcinoma (UTUC); however, there is a lack of data regarding its association with clinicopathologic features as well as survival outcomes. Therefore, we aimed to investigate KMT2D expression, mutation patterns, and their utility as prognostic biomarkers in patients with UTUC. A single-center study was conducted on tumor specimens from 51 patients treated with radical nephroureterectomy (RNU). Analysis of KMT2D protein expression was performed using immunohistochemistry (IHC). Customized next-generation sequencing (NGS) was used to assess alterations in KMT2D exons. Cox regression was used to assess the relationship of KMT2D protein expression and mutational status with survival outcomes. KMT2D expression was increased in patients with a previous history of bladder cancer (25% vs. 0%, p = 0.02). The NGS analysis of KMT2D exons in 27 UTUC tumors revealed a significant association between pathogenic KMT2D variants and tumor location (p = 0.02). Pathogenic KMT2D variants were predominantly found in patients with non-pelvic or multifocal tumors (60% vs. 14%), while the majority of patients with a pelvic tumor location (81% vs. 20%) did not harbor pathogenic KMT2D alterations. Both IHC and NGS analyses of KMT2D failed to detect a statistically significant association between KMT2D protein or KMT2D gene alteration status and clinical variables such as stage/grade of the disease or survival outcomes (all p > 0.05). KMT2D alterations and protein expression were associated with UTUC features such as multifocality, ureteral location, and previous bladder cancer. While KMT2D protein expression and KMT2D mutational status do not seem to have prognostic value in UTUC, they appear to add information to improve clinical decision-making regarding the type of therapy.
Collapse
Affiliation(s)
- Ekaterina Laukhtina
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria; (E.L.); (U.L.); (A.B.); (D.I.); (S.K.); (F.B.); (D.D.); (S.F.S.)
- Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia;
| | - Ursula Lemberger
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria; (E.L.); (U.L.); (A.B.); (D.I.); (S.K.); (F.B.); (D.D.); (S.F.S.)
| | - Andreas Bruchbacher
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria; (E.L.); (U.L.); (A.B.); (D.I.); (S.K.); (F.B.); (D.D.); (S.F.S.)
| | - Dafina Ilijazi
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria; (E.L.); (U.L.); (A.B.); (D.I.); (S.K.); (F.B.); (D.D.); (S.F.S.)
| | - Stephan Korn
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria; (E.L.); (U.L.); (A.B.); (D.I.); (S.K.); (F.B.); (D.D.); (S.F.S.)
| | - Florian Berndl
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria; (E.L.); (U.L.); (A.B.); (D.I.); (S.K.); (F.B.); (D.D.); (S.F.S.)
| | - David D’Andrea
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria; (E.L.); (U.L.); (A.B.); (D.I.); (S.K.); (F.B.); (D.D.); (S.F.S.)
| | - Martin Susani
- Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria; (M.S.); (E.C.)
| | - Dmitry Enikeev
- Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia;
| | - Eva Compérat
- Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria; (M.S.); (E.C.)
| | - Shahrokh F. Shariat
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria; (E.L.); (U.L.); (A.B.); (D.I.); (S.K.); (F.B.); (D.D.); (S.F.S.)
- Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia;
- Karl Landsteiner Institute of Urology and Andrology, 1010 Vienna, Austria
- Department of Urology, Weill Cornell Medical College, New York, NY 10065, USA
- Department of Urology, University of Texas Southwestern, Dallas, TX 75390, USA
- Department of Urology, Second Faculty of Medicine, Charles University, 150 06 Prague, Czech Republic
| | - Melanie R. Hassler
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria; (E.L.); (U.L.); (A.B.); (D.I.); (S.K.); (F.B.); (D.D.); (S.F.S.)
- Correspondence: ; Tel.: +43-140-40026150
| |
Collapse
|